Claire S. Padgett
Chief Tech/Sci/R&D Officer at REGULUS THERAPEUTICS INC.
Profile
Claire S.
Padgett is a professional with experience in clinical operations.
She is currently the Senior Vice President of Clinical Operations at Regulus Therapeutics, Inc. Prior to her current position, she held similar roles at various pharmaceutical companies, including Executive Director of Clinical Operations at Conforma Therapeutics Corp., Vice President of Clinical Operations at Mast Therapeutics, Inc., Vice President of Clinical Operations at Oncolytics Biotech, Inc., and Vice President of Clinical Operations at Cylene Pharmaceuticals, Inc. She also served as Senior Vice President of Clinical Operations at Mirati Therapeutics, Inc. from 2017 to 2018.
Padgett received her undergraduate degree from Rutgers State University of New Jersey, her graduate degree and MBA from Seton Hall University, and her doctorate from Capella University LLC.
Claire S. Padgett active positions
| Companies | Position | Start |
|---|---|---|
| REGULUS THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2022-11-28 |
Former positions of Claire S. Padgett
| Companies | Position | End |
|---|---|---|
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 2018-09-30 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2018-09-30 |
Cylene Pharmaceuticals, Inc.
 Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Chief Operating Officer | 2010-09-27 |
| ONCOLYTICS BIOTECH INC. | Chief Tech/Sci/R&D Officer | - |
Conforma Therapeutics Corp.
 Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Claire S. Padgett
| Rutgers State University of New Jersey | Undergraduate Degree |
| Seton Hall University | Graduate Degree |
| Capella University LLC | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ONCOLYTICS BIOTECH INC. | Health Technology |
| REGULUS THERAPEUTICS INC. | Health Technology |
| Private companies | 4 |
|---|---|
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Health Technology |
Conforma Therapeutics Corp.
Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Claire S. Padgett